GSTP1基因多态性对以DDP为基础的化疗方案治疗晚期胃癌疗效的影响  

Effect of genetic polymorphism of GSTP1 on efficacy of oxaliplatin-based chemotherapy in advanced gastric cancer

作　　者：赵伟庆[1] 蒋敬庭[1] 徐斌[1] 吴骏[1] 张红宇[1] 周文杰[1] 季枚[1] 吴昌平[1] 

机构地区：[1]苏州大学附属第三医院(常州市第一人民医院)肿瘤中心,江苏省213003

出　　处：《江苏医药》2015年第13期1508-1510,共3页Jiangsu Medical Journal

基　　金：常州市卫生局重大招标项目(ZD200810)

摘　　要：目的探讨谷胱甘肽S转移酶P1(GSTP1)基因多态性对以顺铂(DDP)为基础的化疗方案治疗晚期胃癌的疗效及预后的影响。方法晚期胃癌患者59例,按GSTP1基因型分成G/G组、G/A组和A/A组,回顾性分析多西他赛/DDP/5-氟尿嘧啶联合方案化疗疗效和预后。结果G/G组总有效率为73.34%,高于G/A组的19.05%和A/A组的13.04%(P<0.01)。突变基因型(G/G组+G/A组)化疗有效率达41.67%,高于野生基因型(A/A组)的13.04%(P<0.01)。GSTP1G/G基因型患者中位无进展生存时间8.14个月,长于G/A型的4.74个月(P<0.05)。结论GSTP1基因多态性可用于预测DDP为基础的化疗方案治疗晚期胃癌的疗效及预后。Objective To study the effect of genetic polymorphism of glutathione S-transferase P1（GSTP1）on the efficacy of oxaliplatin-based chemotherapy in advanced gastric cancer.Methods On the basis of GSTP1 genotypes,59patients with advanced gastric cancer were assigned into three groups of G/G,G/A and A/A,who received docetaxel/oxaliplatin/5-fluorouracil chemotherapy.The efficacy and prognosis were retrospectively analyzed.Results Total effectiveness rate of G/G group was 73.34%,which was significantly higher than 19.05% of group G/A and 13.04% of group A/A（P〈0.01）.Effectiveness rate of mutant genotypes of groups of G/G and G/A was higher than that of wild genotype（group A/A）（41.67% vs.13.04%）（P〈0.01）.The GSTP1G/G genotype had a median progression-free survival time of 8.14 months,which was significantly longer than 4.74 months of G/A type（P〈0.05）.Conclusion GSTP1 gene polymorphism can be used to predict the efficacy and prognosis in the patients with advanced gastric cancer treated with oxaliplatin-based chemotherapy.

关 键 词：胃癌 谷胱甘肽S转移酶P1 基因多态性 

分 类 号：R735[医药卫生—肿瘤]